Espinoza-Vinces, C. (Christian)

Filtering

2023 - 20242

Settings

Author search.filters.isAuthorOfPublication.463b0ab0-d175-461c-9bef-58f6e22af1ad

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Agrypnia Excitata and Supranuclear Vertical Gaze Palsy Linked to Anti-Ma Encephalitis
    (Wiley Periodicals LLC, 2024) Arbizu, J. (Javier); Espinoza-Vinces, C. (Christian); Horrillo-Maysonnial, A. (Alejandro); Aviles-Olmos, I. (Iciar); Calvo-Imirizaldu, M. (Marta); Pérez-Álvarez, A.I (Ángel Ignacio); Urrestarazu, E. (Elena); Gallego-Perez-Larraya, J. (Jaime)
    Paraneoplastic neurological syndromes result from cancer’s immune impact on the nervous system.1 Anti-Ma-associated encephalitis causes diencephalic, brainstem, and limbic symptoms such as memory loss, narcolepsy and rapid eye movement (REM) behavior disorder (RBD), eye movement abnormalities, and parkinsonism. It can precede cancer diagnosis, often linked to testicular tumors. Agrypnia excitata (AE) is a unique electroclinical syndrome that can disrupt sleep structure with changes in physiological cyclic organization, autonomic overactivity, and oneiric stupor episodes. We report on a patient with anti-Ma encephalitis who exhibits a diencephalic syndrome and AE, not previously reported to our knowledge.
  • Thumbnail Image
    Impact of safinamide on patient-reported outcomes in Parkinson's disease
    (2023) Martí-Andrés, G. (Gloria); Atorrasagasti-Villar, A. (Ainhoa); Espinoza-Vinces, C. (Christian); Villino, R. (Rafael); Luquin-Piudo, M.R. (María Rosario)
    Introduction: Parkinson's disease (PD) is a chronic and progressive neurodegenerative condition due to the degeneration of nigral dopaminergic cells. Both motor and non-motor symptoms (NMS) of PD produce a marked impairment in PD patients' quality of life (QoL), but contrary to motor features, NMS do not improve with dopamine replacement. Novel therapeutic interventions for PD have successfully controlled most motor manifestations of PD, but the management of NMS is still challenging. Since NMS have a negative impact on the QoL of PD patients, researchers are currently looking for drugs that can modulate the activity of neurotransmitter systems other than dopamine in the hope that can alleviate NMS in PD. Among the recently approved drugs for patients experiencing fluctuations in motor symptoms, safinamide stands out as an effective add-on therapy to levodopa. Safinamide is a monoamine oxidase type-B inhibitor (MAOB-I), with proven efficacy in reducing motor fluctuations. Its distinctive mechanism of action impacts dopaminergic pathways via MAOB inhibition and glutamatergic pathways by blocking sodium and calcium channels. Findings from Phase III clinical trials, meta-analysis, post-hoc analysis, and real-life experiences indicate that safinamide benefits motor symptoms such as tremor, bradykinesia, rigidity, and gait. Additionally, it shows promise for improving NMS like fatigue, pain, mood, and sleep disturbances in patients with PD.Areas Covered: In this article, the authors explore the impact of safinamide on patient-reported outcomes in PD. A thorough search was conducted on PubMed focusing on studies published between 2018 and 2023 in English. The inclusion criteria encompassed clinical trials, randomized controlled trials, systematic reviews, meta-analyses, and reviews. The search strategy revolved around the implementation of MeSH terms related to safinamide and its impact on the quality of life in PD.Conclusion: Our data strongly support the improving effect on QoL, reducing the disabling NMS reported in patients with PD.